FDA's Vaccine Chief, Dr. Vinay Prasad, Departs Agency Amid Regulatory Disputes

Dr. Vinay Prasad, the Food and Drug Administration's (FDA) vaccine chief, is departing the agency for the second time in under a year, effective at the end of April. His departure follows a period characterized by several regulatory disputes concerning the review processes for vaccines and specialized drugs. Dr. Prasad is expected to return to his academic position at the University of California, San Francisco.

His departure follows a period characterized by several regulatory disputes concerning the review processes for vaccines and specialized drugs.

Departure Details

FDA Commissioner Marty Makary announced Dr. Prasad's departure to staff via email. This marks Dr. Prasad's second exit from the agency within a year. His previous departure occurred in July, but he was reinstated less than two weeks later with support from Health Secretary Robert F. Kennedy Jr. and Commissioner Makary.

Regulatory Controversies During Tenure

Dr. Prasad's recent tenure included several notable incidents involving the review of medical products.

Moderna's mRNA Flu Vaccine

Dr. Prasad initially refused to allow the FDA to review Moderna's application for a new mRNA influenza vaccine. Three agency officials familiar with the matter stated that a team of career scientists was prepared to review the application. David Kaslow, who heads the vaccine office, reportedly authored a detailed memo advocating for the review.

After Moderna publicly challenged the initial decision, the FDA reversed course and agreed to review the shot, contingent on an additional study.

UniQure's Huntington's Disease Therapy

A dispute arose with UniQure, a company developing an experimental gene therapy for Huntington's Disease. UniQure stated that the FDA was demanding a new trial involving sham surgery, a request the company deemed contradictory to previous FDA guidance and ethically concerning.

The FDA later held a press conference to criticize UniQure's original study, with a senior official stating the product was "stone cold negative" and had "failed."

Dr. Prasad's Regulatory Approach

Dr. Prasad is known as an academic critic of FDA drug review standards. He had previously joined Commissioner Makary in advocating for faster and easier drug reviews. However, his actions as a regulator also involved imposing new warnings and study requirements, particularly for some biotech drugs and COVID vaccines.

Health Secretary Robert F. Kennedy Jr. is identified as a vaccine critic.

Additionally, Dr. Prasad and Tracy Beth Høeg have reportedly assumed control of vaccine surveillance responsibilities from civil servants.